Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Welch Allyn's portable ECG launches

This article was originally published in Clinica

Executive Summary

Welch Allyn is to address the telehealth market with the launch of a portable connectivity-ready electrocardiograph (ECG). The lightweight device, called the CP 50 ECG, is designed for use in settings where flexibility and efficiency are important. It can interface with the Welch Allyn CardioPerfect Workstation Software to connect patient data to electronic health records or a health information system, over the internet or through e-mail. The device comes with an integrated high-resolution thermal printer to generate ECG reports in customisable formats, and it also allows paperless archiving and flexible connectivity options. In addition, the CP 50 provides on-screen instructions that ensure accurate data capture by highlighting poor signals and connections. Welch Allyn said it is addressing the "growing demand" for products with greater efficiency and more connectivity options to move healthcare delivery beyond traditional approaches. The product is scheduled for worldwide release in the coming months, the Skaneateles Falls, New York firm said.

You may also be interested in...

Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts